Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
26.55
-3.80 (-12.52%)
At close: May 30, 2025, 4:00 PM
26.95
+0.40 (1.51%)
After-hours: May 30, 2025, 4:00 PM EDT
Instil Bio Employees
Instil Bio had 14 employees as of December 31, 2024. The number of employees decreased by 35 or -71.43% compared to the previous year.
Employees
14
Change (1Y)
-35
Growth (1Y)
-71.43%
Revenue / Employee
n/a
Profits / Employee
-$5,573,786
Market Cap
174.14M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14 | -35 | -71.43% |
Dec 31, 2023 | 49 | -143 | -74.48% |
Dec 31, 2022 | 192 | -220 | -53.40% |
Dec 31, 2021 | 412 | 262 | 174.67% |
Dec 31, 2020 | 150 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
TIL News
- 9 hours ago - Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 days ago - Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success - Seeking Alpha
- 7 days ago - Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewsWire
- 8 days ago - Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 - GlobeNewsWire
- 17 days ago - Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - GlobeNewsWire
- 5 months ago - Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga